Einav Nili Gal-Yam
Overview
Explore the profile of Einav Nili Gal-Yam including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
2065
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Perry G, Dadiani M, Kahana-Edwin S, Pavlovski A, Markus B, Hornung G, et al.
Mol Carcinog
. 2022 Sep;
61(11):1056-1070.
PMID: 36111610
Abnormal molecular processes occurring throughout the genome leave distinct somatic mutational patterns termed mutational signatures. Exploring the associations between mutational signatures and clinicopathological features can unravel potential mechanisms driving tumorigenic...
12.
Borstnar S, Palacova M, Lacko A, Timcheva C, Nili Gal-Yam E, Papazisis K, et al.
Radiol Oncol
. 2022 May;
56(2):238-247.
PMID: 35575587
Background: The CDK4/6 inhibitor, ribociclib in combination with endocrine therapy significantly improved progression-free survival in the first line setting in post-menopausal patients with HR+/HER2- advanced breast cancer (ABC) in a...
13.
Greenhouse I, Itay A, Sklair Levy M, Lawrence Y, Katzman T, Nili Gal-Yam E
Harefuah
. 2022 Feb;
161(2):73-76.
PMID: 35195966
The SARS-CoV-2 pandemic presents a challenge to health systems in general and for cancer patients in particular. The hurdles of receiving ongoing medical treatment starting from diagnosis through continuous medical...
14.
Baram T, Erlichman N, Dadiani M, Balint-Lahat N, Pavlovski A, Meshel T, et al.
Cells
. 2021 Jul;
10(6).
PMID: 34201054
Triple-negative breast cancer (TNBC) is primarily treated via chemotherapy; in parallel, efforts are made to introduce immunotherapies into TNBC treatment. CD4+ TNFR2+ lymphocytes were reported as Tregs that contribute to...
15.
Aftimos P, Oliveira M, Irrthum A, Fumagalli D, Sotiriou C, Nili Gal-Yam E, et al.
Cancer Discov
. 2021 Jun;
11(11):2796-2811.
PMID: 34183353
AURORA aims to study the processes of relapse in metastatic breast cancer (MBC) by performing multi-omics profiling on paired primary tumors and early-course metastases. Among 381 patients (primary tumor and...
16.
Bernstein-Molho R, Laitman Y, Galper S, Jacobson G, Boursi B, Nili Gal-Yam E, et al.
Int J Radiat Oncol Biol Phys
. 2020 Dec;
109(5):1332-1340.
PMID: 33259931
Purpose: There is a paucity of data on the rates of ipsilateral breast tumor recurrence (IBTR) in BRCA1/2-associated breast cancer (BC). Scarcer yet are outcomes data in BRCA1/2 mutation carriers...
17.
Nejman D, Livyatan I, Fuks G, Gavert N, Zwang Y, Geller L, et al.
Science
. 2020 May;
368(6494):973-980.
PMID: 32467386
Bacteria were first detected in human tumors more than 100 years ago, but the characterization of the tumor microbiome has remained challenging because of its low biomass. We undertook a...
18.
Bernstein-Molho R, Friedman E, Kedar I, Laitman Y, Allweis T, Nili Gal-Yam E, et al.
Breast Cancer Res Treat
. 2020 Apr;
181(2):445-453.
PMID: 32303989
Background: Carriers of pathogenic variants (PVs) in moderate-high-penetrance cancer susceptibility genes are offered tailored surveillance schemes for early cancer diagnosis. The clinical implications of low-penetrance variant carriers are less clear....
19.
Dadiani M, Necula D, Kahana-Edwin S, Oren N, Baram T, Marin I, et al.
Cancer Immunol Immunother
. 2020 Mar;
69(7):1315-1326.
PMID: 32198536
In view of the relatively limited efficacy of immunotherapies targeting the PD-1-PD-L1 axis in triple-negative breast cancer (TNBC) and of published reports on tumor-promoting roles of TNFR2+ tumor-infiltrating lymphocytes (TNFR2+...
20.
Zundelevich A, Dadiani M, Kahana-Edwin S, Itay A, Sella T, Gadot M, et al.
Breast Cancer Res
. 2020 Mar;
22(1):28.
PMID: 32164744
After the publication of the original article [1], we were notified the upper panel of the Fig. 1, where the patients' codes are listed, was cropped by mistake so the...